JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Janux Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$16.74+0.23 (+1.39%)

Close on Oct 19, 2026

Market cap: $1.05B
P/E (TTM): –
Dividend yield: –

Janux Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	10	11	8.08	8.61	3.64	0
Research & Development	126	68	55	53	26	3.04
General & Administrative	42	41	26	22	10	1.80
Operating Income	-158	-99	-73	-67	-33	-4.84
Other Non-Operating Income	44	30	15	4.03	0.26	-1.94
Asset Impairment Charges	–	–	–	0	0	–
Gain (Loss) on Investments	–	–	–	0	0	–
Gain (Loss) on Sale of Assets	–	–	–	0	0.00	0
Income Tax Expense	0	0	0	–	–	–
Net Income incl. Noncontrolling Interests	-114	-69	-58	-63	-33	-6.78
Net Income	-114	-69	-58	-63	-33	-6.78
EPS (Basic)(per share)	-1.83	-1.28	-1.32	-1.52	-1.39	-7.41
EPS (Diluted)(per share)	-1.83	-1.28	-1.32	-1.52	-1.39	-7.41
Shares Outstanding (Basic, Weighted)(shares)	62	54	44	41	24	0.23
Shares Outstanding (Diluted, Weighted)(shares)	62	54	44	41	24	0.92

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -598.1%
Net margin: -427.5%
Return on equity, FY2025: -11.5%

Financial strength

Current ratio: 16.35
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 46.2%

Valuation

P/E ratio: –
Price to sales: 43.90
Price to book: 1.14
Dividend yield: –